ǰÑÔ
Âѳ²°©(ovarian carcinoma)ÊÇÅ®ÐÔÉúֳϵͳ³£¼ûµÄ¶ñÐÔÖ×Áö£¬Æä·¢²¡ÂÊ¡¢²¡ËÀÂʾù¾Ó¸¾¿Æ¶ñÐÔÖ×ÁöǰÏß¡£ÏÖÔÚ½¨ÉèÂѳ²°©¶¯ÎïÄ£×ÓµÄÒªÁìÓÐ×Ô¾õÐÔµÄÂѳ²Ö×Áö¶¯ÎïÄ£×Ó¡¢ÌåÍâת»¯Âѳ²ÉÏÆ¤Ï¸°ûµÄÒÆÖ²Áö¡¢Ö°©ÎïÓÕ·¢Âѳ²Ö×ÁöÒÔ¼°»ùÒò¹¤³ÌÂѳ²Ö×Áö¶¯ÎïÄ£×Ó¡£
½üÄêÀ´£¬Ëæ×ÅÐÂÊÖÒÕÉú³¤£¬»ùÒò¹¤³ÌË¢ÐÂСÊóµÄÂѳ²ÉÏÆ¤ÐÔ°©Ä£×ÓÖð½¥Éú³¤¼°Ó¦ÓÃÆðÀ´¡£ÓëÒÔÍù¹Å°å»¯Ñ§Ö°©ÎïÓÕµ¼¶¯ÎïÄ£×ÓÏà±È£¬Ê¹ÓÃת»ùÒòÊÖÒÕ½«Ö×ÁöÐγÉÏà¹Ø»ùÒòתÈ붯ÎïÌåÄÚ¾ÙÐбí´ï¶ø½¨ÉèµÄÖ×ÁöÄ£×ÓµÄÖ°©Àú³ÌºÍ²¡ÀíÌåÏÖ¸ü¿¿½üÈËÌå¡£²¢ÇÒ£¬ÔÚÖ×ÁöÐγɵÄÓÕµ¼Àú³ÌÖУ¬¿ÉÔÚ×ÔȻ״̬Ï´ÙʹÕý³£Ï¸°ûÏòÖ×Áöϸ°ûÑݱ䣬ͬʱÖÖÖÖ°©Ç°²¡±ä¾ù¿ÉÏÔʾ£¬´Ó¶ø¸üÀûÓÚ¾ÙÐÐÖ×ÁöÐγɵÄÑо¿¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
ʹÓÃת»ùÒòÊÖÒÕ£¬½«»ùÒòµÄDNAƬ¶Ï×¢ÈëÊܾ«ÂÑ»òÓÃÖØ×鲡¶¾Ð¯´øÄ¿µÄ»ùÒòѬȾÔçÆÚÅßÌ¥£¬Ê¹³öÉúµÄСÊó±í´ïÓÐij¸öÄ¿µÄ»ùÒò£¬ÈçһЩ°©»ùÒò£¬´Ó¶øÊÓ²ìÕâ¸ö»ùÒò¶ÔÖ×Áö±¬·¢µÄÓ°Ïì¡£ÏÖÔÚÓÃת»ùÒòÊóÈ¥Ñо¿Âѳ²°©µÄ±¬·¢Éú³¤£¬¼¯ÖÐÔÚÂѳ²ÌØÒìÐÔµÄÆô¶¯×ÓÊÇΪÁËÈ·±£Ä¿µÄ»ùÒò½ö ÔÚÂѳ²ÉÏÆ¤Ï¸°û(ovarian surface epithelium,OSE)±í´ï¶ø²»ÔÚÆäËû×éÖ¯Öбí´ï£¬´Ó¶ø¸üºÃµØÄ£ÄâÈËÀàÂѳ²°©µÄ±¬·¢¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
1.ÏÔ΢עÉä·¨ÖÆ±¸×ª»ùÒò¶¯ÎïÄ£×Ó ÓÃÓÚÏÔ΢עÉäµÄÂѳ²°©×ª»ùÒò¶¯ÎïÄ£×ӵįô¶¯×ÓÓÐinhibin-alpha¡¢OSP-1ºÍMIS¢òRÆô¶¯×Ó¡£ÓÃinhibinalphaÆô¶¯×Ó£¬½«SV40 TAg(large SV40 T antigen)ÓÃת»ùÒòÒªÁìʹÆäÔÚÁ£²ãϸ°û±í´ï¶øÓÕ·¢ÁËÁ£²ãϸ°ûÁö¡£OSP-1(ovarian specific promoter)Æô¶¯×ÓÄÜʹĿµÄ»ùÒòÌØÒìÐÔµØÔÚÕý³£Âѳ²ÉÏÆ¤¼°Âѳ²°©Ï¸°û±í´ï£¬µ±×ªÈëLacZ»ùÒòºó£¬ÓÃX-galȾɫҪÁì¼ì²â¶à¸öÆ÷¹Ù·¢Ã÷£¬LacZµÄ±í´ï½ö¾ÖÏÞÔÚÂѳ²¡£µ«ÓÃOSP-1×÷ΪÆô¶¯×Ó£¬SV40TAgת»ùÒò´óÊóÖ×Áö¶¯ÎïÄ£×ÓÖУ¬³ýÂѳ²Í⣬ÆäËû¶à´¦×éÖ¯»¹±¬·¢Ö×Áö£¬Òò´Ë£¬Ö»¹ÜOSP-1ʹĿµÄ»ùÒòÖ÷ÒªÔÚÂѳ²×ªÂ¼£¬µ«ÕæÕýÕÕ¾Éȱ·¦ÌØÒìÐÔ£¬Õվɲ»¿É×èÖ¹µØÊ¹SV40TAgÔÚÆäËûÉÙÊýµÄ×éÖ¯±í´ï¶ø±¬·¢Ö×Áö¡£ÁíÍâÒ»¸öÊÇÆô¶¯×ÓMIS¢òR (the Mullerian inhibitory substance type ¢ò receptor),MIS¢òRµÄ±í´ï½ö¾ÖÏÞÓÚÅß̥ʱÆÚÃçÀÕ¹ÜÖÜΧµÄ¼äÖÊϸ°û¡¢ÅßÌ¥¹Ü×´ºÍÁÑÅÝ×´ÐÔÏÙϸ°û¡¢³ÉÄêØºÍèµÄSertoliºÍLeydigϸ°û£¬Âѳ²µÄÁ£²ãϸ°û£¬ÆäÓÐǿʢµÄÆô¶¯¹¦Ð§ºÍ¶ÔÂѳ²ÓÐÌØÒìÐÔ£¬ÔÚÈËÂѳ²°©Ï¸°ûϵÖпɼûÓÐMIS¢òRµÄ±í´ï¡£2003Ä꣬ConnollyµÈÊ×´ÎÀÖ³Éͨ¹ýÃçÀÕ¹ÜÒÖÖÆÎï¢ò»ùÒòÆô¶¯×ÓµÄת»ùÒòµ÷¿Ø±í´ïÔçÆÚSV40TAg»ùÒò£¬½¨Éè±í´ï½¬ÒºÐÔÂѳ²ÉÏÆ¤ÐÔ°©²¡ÀýÌØÕ÷µÄ×Ô¾õÂѳ²°©×ª»ùÒòСÊóÄ£×Ó¡£ÓÃMIS¢òR×÷ΪÆô¶¯×Ó½«SV40TAgÊܾ«ÂÑÏÔ΢עÉäµÄÒªÁ챬·¢×ª»ùÒòÊ󣬳öÉúºóÄܹ»Áè¼Ý50£¥µÄСÊóË«²àÂѳ²±¬·¢Âѳ²°©£¬µ«Ò²ÓÐÉöºÍÄÔÖ×ÁöµÄ±¬·¢¡£
2.ÖØ×鲡¶¾Ð¯´øÄ¿µÄ»ùÒòÖ±½ÓÄÒÄÚ×¢ÉäÓÕ·¢Âѳ²Ö×Áö ½«ÖØ×éµÄЯ´øÓÐÄ¿µÄ»ùÒòµÄÏÙ²¡¶¾ÓÃÄÚ×¢ÉäµÄÒªÁì×¢É䵽СÊóÂѳ²µÄ°üĤÏ£¬Í¨¹ýÏÙ²¡¶¾Ñ¬È¾OSEϸ°û£¬¶ø½«Ä¿µÄ»ùÒòתµ¼ÈëOSEϸ°û£¬ÕâÖÖÒªÁìÄܹ»ºÜºÃµØÄ£ÄâÔÚÔçÆÚÂѳ²°©±¬·¢Ê±Ìåϸ°ûÍ»±äʱµÄÇéÐΡ£×î½üÓб¨¸æÓÃÕâÖÖÒªÁ콫Cre-loxPתÈëOSEϸ°û£¬´Ó¶ø×è¶ÏÁËp53ºÍRbµÄ±í´ï¶ø±¬·¢Ö×Áö¡£ÒòСÊóÂѳ²ÏåÄܾÖÏÞÐÔת´ïCreÖØ×éÏÙ²¡¶¾£¬´ó×ÚѧÕß½«ÆäÔËÓÃÓÚÂѳ²ÍâòÉÏÆ¤£¬Ê¹CreÖØ×éø£P1½»Á÷λµãÐòÁÐ(Cre-LoxP)ÖнéµÄ»ùÒòʧ»î£¬Ìõ¼þÐԵرí´ïÖ×ÁöÒÖÖÆ»ùÒò£¬´Ó¶ø½¨ÉèÂѳ²°©»ùÒò¹¤³ÌÄ£×Ó¡£
Ò¦µÂÉúÓÃЯ´øÓÐc-MycºÍk-Ras»ùÒòµÄÖØ×鷴ת¼²¡¶¾Ñ¬È¾OSEºó£¬½«RasºÍRM×éϸ°û¸¹Ç»×¢ÉäÓÚÂãÊóÌåÄÚ£¬ÀÖ³ÉÖÆ±¸Ð¡ÊóÂѳ²°©¶¯ÎïÄ£×Ó¡£Í»±äµÄk-Ras×÷Ϊһ¸ö°©»ùÒò£¬Äܹ»Ôö½øOSEϸ°ûµÄÔöÖ³£¬¸¶ÓëOSEÇÖÏ®µÄÄÜÁ¦£¬Í¬Ê±¿ÉʹOSE±¬·¢¶ñÐÔת»¯¡£c-Myc×÷Ϊһ¸öºËת¼µ÷ÀíÒò×Ó£¬µ¥¶À²»¿Éʹϸ°ûÔöÖ³¼ÓËÙ£¬Ò²²»¿ÉʹOSE±¬·¢¶ñÐÔת»¯£¬ÔÚÌåÄÚÒ²²»¿ÉÐγÉÖ×Áö£¬µ«¿ÉÐͬÆäËûÒò×ÓÈçk-Ras£¬ÔöÇ¿Æä¹¦Ð§£¬¸¶Óëϸ°û¸üÇ¿µÄÉú³¤ºÍÇÖÏ®ÄÜÁ¦¡£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
ת»ùÒòÊóÂѳ²°©¶¯ÎïÄ£×ÓÊÇÑо¿Âѳ²°©±¬·¢µÄ¼«ÎªÓмÛÖµµÄ¶¯ÎïÄ£×Ó£¬ÕâÖÖÄ£×Óͨ¹ýÖÖÖÖ¸÷ÑùµÄÒªÁ죬ȥÏàʶºÍÑо¿ÖÖÖÖÒòËØ¶ÔÂѳ²°©±¬·¢ËùÆðµÄ×÷Óã¬ÌØÊâÊÇһЩ°©»ùÒòºÍÒÖ°©»ùÒòÔÚÖ×Áö±¬·¢Éú³¤Àú³ÌÖÐÊÇÔõÑùʩչ×÷Óõģ¬¿ÉÒÔͨ¹ýʹÓþßÓвî±ðÒÅ´«Åä¾°µÄƷϵµÄСÊó£¬Ñо¿²î±ðÒòËØµÄÏ໥×÷Ó㬺ñȿÉÒÔÑ¡Óòî±ðÅÅÂÑÆµÂÊ¡¢²î±ð¼¤ËØË®Æ½µÄƷϵ¶øÊ¹ÊµÑéµÖ´ï²î±ðÄ¿µÄ¡£ÕâÖÖÄ£×Ó»¹¿ÉÒÔ×ÊÖúÎÒÃÇÏàʶÖ×ÁöÊÇÔõÑù´ÓOSEϸ°û±äΪÖ×Áöϸ°û£¬ÕâÖÖת»ùÒòµÄÄ£×Ó²î±ðÓÚÒÔÍùµÄÒÆÖ²ÁöÄ£×Ó£¬ÕâÖÖÄ£×Ó¿ÉÒÔÑо¿Ò»Ð©ÒÅ´«Ö²¡ÒòËØÔÚÂѳ²°©±¬·¢µÄ²î±ðʱÆÚµÄ×÷Óã¬ÌØÊâÊÇÔçÆÚ¸Õ¸Õ×îÏȱ¬·¢°©±äʱ£¬ÈçÔλ°©½×¶Î¡£´ËÄ£×Ó¿É×÷ΪÆÀ¹À·Ö×Ó°ÐÏòÖÎÁƵÄÁÙ´²Ç°ÆÚÄ£×Ó£¬ÓÈÆä¹ØÓÚÒ»Ð©ÌØ¶¨µÄÉÏÆ¤ÐÔÂѳ²°©ÑÇÐ͸üÓÐÁÙ´²ÒâÒ塣ʹÓÃת»ùÒòÊÖÒÕ½«Ö×ÁöÐγÉÏà¹Ø»ùÒòתÈ붯ÎïÌåÄÚ¾ÙÐбí´ï½¨ÉèµÄÖ×ÁöÄ£×ÓµÄÖ°©Àú³ÌºÍ²¡ÀíÌåÏÖ¸ü¿¿½üÈËÌ壬´Ó¶øÎªÌ½Ë÷ÈËÂѳ²°©µÄ²¡Òò¼°·¢²¡»úÖÆ¡¢·¢²¡Àú³Ì¡¢×ªÒÆ¡¢¶àÒ©ÄÍÒ©µÈÉúÎïѧÐÐΪÌṩÁËÒ»ÖÖ¿É¿¿ÊֶΡ£
²Î¿¼ÎÄÏ×£º
1.Òü°®À¼£¬ÖÓ÷£¬Ëï¹ðÇÛ£¬µÈ£®ÂÌɫӫ¹âÂѰױê¼ÇµÄÈËÂѳ²°©ÂãÊóÔÎ»ÒÆÖ²Ä£×ӵĽ¨É裮ÄÏ·½Ò½¿Æ´óѧѧ±¨£¬2008,28 (3):484-486
2.ãÆÖÒöΣ¬º«·ï¾ê£¬µÔСÁú£¬µÈ£®Âѳ²°©ÂãÊóÒÆÖ²ÁöÄ£×Ó±ÈÕպͿÉÊÓ»¯Ñо¿Ï£Íû£®ÌìÏÂÖÐÎ÷ҽ͎áÔÓÖ¾£¬2012, 7 (7):636-638
3.ÇñÀö骣¬º«·ç¾ê£¬·¶ÏÔ×Å£¬µÈ£®Á½ÖÖÓÕ·¢Fischer344´óÊóÂѳ²°©¶¯ÎïÄ£×Ó½¨ÉèÒªÁìµÄ½ÏÁ¿. ÌìÏÂÖÐÎ÷ҽ͎áÔÓÖ¾£¬2010,5(6):488-490
4.Ò¦µÂÉú£®ÖØ×鷴ת¼²¡¶¾½éµ¼µÄk-Ras/c-MycСÊóÂѳ²°©¶¯ÎïÄ£×ӵĽ¨ÉèºÍÒÖ°©»ùÒòOPCMLµÄ¿Ë¡¼°ÆäÔÚÂѳ²°©ÖеĹ¦Ð§Ñо¿£®¹ãÎ÷Ò½¿Æ´óѧ²©Ê¿Ñ§Î»ÂÛÎÄ£¬2005
5.Àè¾²£¬ÍõÑ©·É£¬ÖÓ÷£®ÕûÌå¿ÉÊÓ»¯Âѳ²°©Ôλ¼°×ªÒƶ¯ÎïÄ£×ӵĽ¨É裮¹ã¶«Ò½Ñ§£¬2012, 33 (7):887-889
6.öÄȫУ¬ÃÓÈôÈ». ת»ùÒò¶¯ÎïÔÚÂѳ²Ö×ÁöÑо¿ÖеÄÓ¦Óã®ÍâÑóҽѧ¸¾²ú¿ÆÑ§·Ö²á£¬2003,30 (6):391-393
7.Connolly DC, Bao R, Nikitin AY, el al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MlSilR promoter develop epithelial ovarian cancer, Cancer res 2003, 63 (6): 1389-1397
8.Dutertre M, Couédard L, Xavier F, el al. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Müllerian hormone in transgenic mice. Endocri.nology, 2001, 142 (9):4040-4046
9.Carson K, Macdonald E, Dube M, et al. Generali on of tumors in transgece mice expressing the SV40 T antigen under the control of ovarian-specific promoter 1. J Soc Cynecol lnvestig,2003,10(4):244-250
10.Hoffman RM. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherap. Methods Mol Med,2005, 111 :297-322
11.Kananen K, Markkula M, Rainio E, et al. Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha-subunit promoter/simian virus T-antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Mol Endocrinol, 1995,9 (5):616-627
12.Selvakumaran M, Bao R, Crijns AP, el al. Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res,2001, 61 (4):1291-1295